Patient Square Capital LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Patient Square Capital LP
CRD #312203
SEC #801-120508
CIK #0001819257, 0001827614
AUM 17.51 B (2026-05-26)
Employees 97 (52% Investors, 3% Brokers)
Fees
Minimum
Phone650-677-8100
Address2884 Sand Hill Road
Menlo Park, CA 94025
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
2016128402010201520212027
In the News
Wed, 24 Jun 2026 Osanni Bio closes $190M Series B led by Patient Square Capital — Dealroom
Wed, 06 May 2026 Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor — Business Wire
Wed, 06 May 2026 Patient Square Capital Names Timothy P. Walbert Senior Advisor — citybiz
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5. Fees and Compensation

In general, Patient Square receives a management fee and a carried interest in connection with
advisory services. Except as otherwise described in “Valuation Creation Function Personnel”,
“Covered In-House Services,” “Broker-Dealer Affiliate” and “Senior Advisors” below, Patient
Square, or other Patient Square entities or affiliates receive additional compensation in
connection with management and other services performed for portfolio companies of Funds and
such additional compensation will offset in whole or in part the Management Fees (as defined
below) otherwise payable to Patient Square in accordance with the applicable Governing
Documents. In addition, in certain circumstances, Patient Square is permitted to receive
compensation for management and other services performed in connection with co-investments
made in portfolio companies of the Funds. Investors in the Funds also bear certain expenses,
including expenses of Patient Square and its affiliates in accordance with the applicable
Governing Documents.
Management Fees
Subject to the specific provisions in each Fund’s Governing Documents, a Fund will generally pay
Patient Square, quarterly and in advance, a management fee (the “Management Fee”), although
certain Funds (or Investors in those Funds) will not be required to pay a management fee.
Management Fees will be calculated and charged on a basis that is generally not tied to the
Fund’s then-current net asset value. From the effective date of the relevant Fund until a date
specified in the Governing Documents (generally representing the date Patient Square first
receives or begins to accrue management fees with respect to a new blind pool, equity investment
fund with objectives, strategy, scope, and investment criteria substantially similar to those of such
Fund or the end of the Fund’s investment period, the “Stepdown Date”), Management Fees
generally will be up to 2% of aggregate Investor capital commitments (“Commitments”). Investors
participating in a closing after the Effective Date (as defined in the Governing Documents,
generally representing the later of (i) the date of which the relevant General Partner notifies the
Limited Partners that the General Partner in its sole discretion has determined that its partners
have commenced identifying and investigating new investment opportunities for the Fund or (ii)
the initial closing date) bear the Management Fee from such date, generally in addition to an
interest component payable to Patient Square or an affiliate. After the Stepdown Date,
Management Fees will generally be up to 2% of the aggregate unrecouped bridge financing and
investment contributions (including, where applicable, a Fund borrowing component and the
amount of any capitalized Transaction Fees (as defined below) or expenses) made or payable to

a Fund with respect to portfolio company investments that have not been disposed of less the
aggregate amount of any permanent write downs of investments that have not been disposed of
(such investments, “Impaired Value Investments”), in each case as determined on the first day of
the period to which the Management Fee relates. With respect to certain Funds, the Management
Fee rate may be reduced or otherwise adjusted during any extension of a Fund's term beyond its
initial term, as determined by the applicable General Partner and as further described in the
applicable Governing Documents. Due to potential differences in the criteria set forth in their
respective Governing Documents, in the event where more than one Fund participates in an
investment, there is the possibility that an investment will become an Impaired Value Investment
for purposes of one Fund’s Governing Documents but not those of one or more other Funds.

The amount of Management Fees generally will not correspond with fluctuations in a Fund’s net
asset value, including following the investment period, and will only be reduced, if at all, as a result
of the relevant Impaired Value Investment standard. Further, once paid or accrued, Management
Fees generally will not be reimbursed or refunded under the Governing Documents in the event
of realizations, dispositions or write-downs that occur partway through the relevant calculation
period or other events not constituting a complete realization, such as a partial sale or disposition,
reorganizations, recapitalization (including recapitalizations involving dividends), roll-over
investment in connection with a sale or dividend distribution, except in the case of investments
meeting the relevant Impaired Value Investment standard under the Governing Documents.
Except where a Fund’s Governing Documents expressly provide to the contrary, Management
Fees will not be reduced (in whole or in part) in the case of partial sales, distributions or
dispositions of investments. Additionally, after the Stepdown Date, where there has been a partial
distribution, partial write-down or partial sale of an investment, and the fair market value of the
remaining portion of such investment following such event exceeds the total amount of investment
contributions relating to such investment, Management Fees will generally not be reduced.

In many circumstances, the Management Fee base of such post-Stepdown Date Management
Fees will include capitalized transaction-specific fees and expenses of unrealized investments,
including certain fees (such as Transaction Fees) and expenses paid to service providers
(including suppliers, vendors, consultants, lenders, law firms including Fund or transaction
counsel), transaction service providers and their respective affiliates, personnel and related
investment vehicles (together, “Service Providers”), VCF Personnel (as defined below), Senior
Advisors, the Broker-Dealer Affiliate, third parties, Patient Square or its affiliates.

The Governing Documents set forth the full list of terms under which Management Fees will be
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7. Types of Clients

As described in Item 4 above, Patient Square provides investment advice to the Funds that are
exempt from registration as an investment company under the Investment Company Act and
whose interests are not registered under the Securities Act. Investors in the Funds include
institutions, sovereign wealth funds, pension funds, endowments, foundations, family offices,
health systems, consultants, private wealth platforms, insurance companies, high net-worth
individuals, trusts funds of funds, and other sophisticated investors that meet certain qualification
requirements. The Funds generally have a minimum investment amount of $10,000,000 for third-
party Investors, and the Funds’ interests are offered and sold solely to qualified purchasers (or
qualified knowledgeable Patient Square personnel), which may be waived on a case-by-case
basis subject to Patient Square’s discretion.
CIK Period
0001819257 0001827614
Sector Form 13F Holdings Value ($M)
Roivant Sciences Ltd 226.2
Argenx SE 26.8
Insmed Inc 25.8
BeiGene Ltd 23.9
UNUM Therapeutics Inc 22.9
Mirum Pharmaceuticals Inc 21.2
Belite Bio Inc 18.6
Legend Biotech Corp 17.9
Nektar Therapeutics 15.1
DBV Technologies Sa 14.5
Pharvaris NV 13.9
Abivax Sa 13.5
Xenon Pharmaceuticals Inc 13.2
Celcuity Inc 10.8
Psivida Corp 10.2
Merck & Co Inc 9.6
Arcutis Biotherapeutics Inc 9.4
Allogene Therapeutics Inc 8.4
Kymera Therapeutics Inc 8.3
Magenta Therapeutics Inc 7.9
Imara Inc 7.8
Isoray Inc 6.8
MIND Medicine Mindmed Inc 6.3
Transdel Pharmaceuticals Inc 5.8
Proteon Therapeutics Inc 5.4
CytomX Therapeutics Inc 5.1
Arcus Biosciences Inc 4.2
Ventrus Biosciences Inc 3.8
Aeglea Biotherapeutics Inc 0.1
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
PE 27 Patient Square Paradigm Coinvest LP [2026-03-31] 500.0 M
Filed 2025-02-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE 28 Patient Square Premium Coinvest LP [2026-03-31] 50.0 M
Filed 2025-11-14 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE 29 Blackwell Capital Partners II LP [2026-03-31] 1,517.6 M
Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE 30 Redwood Capital Discretionary Partners LP [2026-03-31] 13.8 M
Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE 20 Patient Square Equity Executives II LP 2025-03-26
PE 21 Patient Square Equity Executives QP II LP [2025-03-26]
Filed 2026-03-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE 22 Patient Square Equity Partners II LP [2025-03-26] 3,111.0 M 1,510.7 M
Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE 23 Patient Square Equity Partners II-A LP [2025-03-26] 3,111.0 M 1,510.7 M
Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE 24 Patient Square Equity Partners II-B LP 2025-03-26 297.6 M
PE 25 Patient Square Equity Co-Invest II LP [2025-03-26] 61.2 M 61.2 M
Filed 2025-11-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 30 17.5
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 30 17.5
By Discretionary
Discretionary 30 17.5
Non-Discretionary 0 0.0
Total 30 17.5
By Non-United States Persons
Non-United States Persons 6.9
United States Persons 10.7
Total 30 17.5
Form D Directors Role # Filings # Firms 2011 - 2026
James Momtazee Executive Officer 44 3
Adam Fliss Executive Officer 35 2
Maria Walker Executive Officer 24 2
Carolyn Drayer-Greenwalt Executive Officer 4 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001819257]
3 [0001827614]
4 [0001827614]
SC 13G [0001827614]
Form 13D/13G Filer Form 13D/13G Subject Filed
Patient Square Capital LLC Montes Archimedes Acquisition Corp [2021-02-11]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesPrivate Equity
Form 3/4/5 Subject 2011 - 2026
Montes Archimedes Acquisition Corp
Patient Square Capital LLC
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Montes Archimedes Acquisition Corp MAAC
Class B common stock · derivative
2021-09-30 Grant 10,167,956
Montes Archimedes Acquisition Corp MAAC
Class B common stock · derivative
2020-11-20 Other 1,232,044
Comparable Firms State AUM
American Securities LLC
NY 18.91 B
Monroe Capital Management Advisors LLC
IL 18.56 B
1823 Partners US LLC
FL 18.53 B
Arctos Partners LP
TX 18.22 B
RCP Advisors 2 LLC
TX 18.21 B
Arlington Management Employees LLC
MD 18.19 B
Atlas FRM LLC
CT 18.12 B
Invesco Loan Manager LLC
NY 17.69 B
Searchlight Capital Partners LP
NY 17.51 B
Niobrara Capital Partners LP
NY 17.07 B
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com